Rituximab Monotherapy versus Rituximab and Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy

Rituximab Monotherapy versus Rituximab and Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy

Abstract Purpose: To study whether rituximab and bortezomib combination therapy is more effective than rituximab monotherapy in the treatment of non-paraneoplastic autoimmune retinopathy (npAIR). Methods: Retrospective case series involving six patients with npAIR, taking either rituximab and bortez...

Full description

Bibliographic Details
Main Authors: Arash Maleki, Amanda Colombo, Sydney Look-Why, BA; Peter Y Chang, Stephen D Anesi
Format: Article
Language:English
Published: Knowledge E 2022-11-01
Series:Journal of Ophthalmic & Vision Research
Subjects:
autoimmune retinopathy
bortezomib
electroretinography
non-paraneoplastic air
rituximab
visual field
Online Access:https://doi.org/10.18502/jovr.v17i4.12304

Internet

https://doi.org/10.18502/jovr.v17i4.12304

Similar Items